Litcius/Paper detail

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial

Douglas Adkins, Jessica Ley, Jingxia Liu, Peter Oppelt

2024The Lancet Oncology10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRamucirumabPembrolizumabOncologyClinical endpointInternal medicinePhases of clinical researchHead and neck squamous-cell carcinomaResponse Evaluation Criteria in Solid TumorsHead and neck cancerClinical trialCancerImmunotherapyHead and Neck Cancer StudiesAngiogenesis and VEGF in CancerEsophageal Cancer Research and Treatment
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial | Litcius